Your browser doesn't support javascript.
loading
Hemizygous variants in protein phosphatase 1 regulatory subunit 3F (PPP1R3F) are associated with a neurodevelopmental disorder characterized by developmental delay, intellectual disability and autistic features.
Liu, Zhigang; Xin, Baozhong; Smith, Iris N; Sency, Valerie; Szekely, Julia; Alkelai, Anna; Shuldiner, Alan; Efthymiou, Stephanie; Rajabi, Farrah; Coury, Stephanie; Brownstein, Catherine A; Rudnik-Schöneborn, Sabine; Bruel, Ange-Line; Thevenon, Julien; Zeidler, Shimriet; Jayakar, Parul; Schmidt, Axel; Cremer, Kirsten; Engels, Hartmut; Peters, Sophia O; Zaki, Maha S; Duan, Ruizhi; Zhu, Changlian; Xu, Yiran; Gao, Chao; Sepulveda-Morales, Tania; Maroofian, Reza; Alkhawaja, Issam A; Khawaja, Mariam; Alhalasah, Hunaida; Houlden, Henry; Madden, Jill A; Turchetti, Valentina; Marafi, Dana; Agrawal, Pankaj B; Schatz, Ulrich; Rotenberg, Ari; Rotenberg, Joshua; Mancini, Grazia M S; Bakhtiari, Somayeh; Kruer, Michael; Thiffault, Isabelle; Hirsch, Steffen; Hempel, Maja; Stühn, Lara G; Haack, Tobias B; Posey, Jennifer E; Lupski, James R; Lee, Hyunpil; Sarn, Nicholas B.
Afiliação
  • Liu Z; Genomic Medicine Institute, Cleveland Clinic Lerner Research Institute, Cleveland, OH 44195, USA.
  • Xin B; DDC Clinic for Special Needs Children, Middlefield, OH 44062, USA.
  • Smith IN; Genomic Medicine Institute, Cleveland Clinic Lerner Research Institute, Cleveland, OH 44195, USA.
  • Sency V; DDC Clinic for Special Needs Children, Middlefield, OH 44062, USA.
  • Szekely J; DDC Clinic for Special Needs Children, Middlefield, OH 44062, USA.
  • Alkelai A; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Shuldiner A; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Efthymiou S; Department of Neuromuscular Disorders, University College London (UCL) Institute of Neurology, London WC1N 3BG, UK.
  • Rajabi F; Division of Genetics & Genomics, Boston Children's Hospital, Boston, MA 02115, USA.
  • Coury S; Division of Genetics & Genomics, Boston Children's Hospital, Boston, MA 02115, USA.
  • Brownstein CA; Division of Genetics & Genomics, Boston Children's Hospital, Boston, MA 02115, USA.
  • Rudnik-Schöneborn S; The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, MA 02115, USA.
  • Bruel AL; Institute for Human Genetics, Medical University Innsbruck, Innsbruck 6020, Austria.
  • Thevenon J; Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne, Dijon 21000, France.
  • Zeidler S; UF Innovation en diagnostic génomique des maladies rares, CHU Dijon Bourgogne, Dijon 21000, France.
  • Jayakar P; Université Grenoble Alpes, Institute for Advanced Biosciences, Grenoble, France.
  • Schmidt A; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam 3015 GD, The Netherlands.
  • Cremer K; Division of Genetics and Metabolism, Nicklaus Children's Hospital, Miami, FL 33155, USA.
  • Engels H; Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, 53105 Bonn, Germany.
  • Peters SO; Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, 53105 Bonn, Germany.
  • Zaki MS; Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, 53105 Bonn, Germany.
  • Duan R; Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, 53105 Bonn, Germany.
  • Zhu C; Clinical Genetics Department, Human Genetics and Genome Research Institute National Research Centre, Cairo 12622, Egypt.
  • Xu Y; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
  • Gao C; Center for Brain Repair and Rehabilitation, Institute of Neuroscience and Physiology, University of Gothenburg, Göteborg 417 56, Sweden.
  • Sepulveda-Morales T; Henan Key Laboratory of Child Brain Injury and Henan Pediatric Clinical Research Center, Institute of Neuroscience and Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
  • Maroofian R; Henan Key Laboratory of Child Brain Injury and Henan Pediatric Clinical Research Center, Institute of Neuroscience and Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
  • Alkhawaja IA; Department of Pediatric Rehabilitation Medicine, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou 450012, China.
  • Khawaja M; International Laboratory for Human Genome Research, Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Juriquilla, Querétaro 76226, México.
  • Alhalasah H; Department of Neuromuscular Disorders, University College London (UCL) Institute of Neurology, London WC1N 3BG, UK.
  • Houlden H; Al-Bashir Hospital, Pediatric Department, Pediatric Neurology Unit, Amman, Jordan.
  • Madden JA; Prince Hamzah Hospital, Amman, Jordan.
  • Turchetti V; Hospital Clínic and Fundació Hospital Sant Joan de Déu de Martorell/Barcelona, Barcelona, Spain.
  • Marafi D; Al-Karak Government Teaching Hospital, Al-Karak, Jordan.
  • Agrawal PB; Department of Neuromuscular Disorders, University College London (UCL) Institute of Neurology, London WC1N 3BG, UK.
  • Schatz U; Division of Genetics & Genomics, Boston Children's Hospital, Boston, MA 02115, USA.
  • Rotenberg A; The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, MA 02115, USA.
  • Rotenberg J; Department of Neuromuscular Disorders, University College London (UCL) Institute of Neurology, London WC1N 3BG, UK.
  • Mancini GMS; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
  • Bakhtiari S; Department of Pediatrics, Faculty of Medicine, Kuwait University, Kuwait City 13060, Kuwait.
  • Kruer M; Division of Genetics & Genomics, Boston Children's Hospital, Boston, MA 02115, USA.
  • Thiffault I; The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, MA 02115, USA.
  • Hirsch S; Division of Neonatology, Department of Pediatrics, University of Miami School of Medicine and Jackson Health System, Miami, FL 33136, USA.
  • Hempel M; Institute for Human Genetics, Medical University Innsbruck, Innsbruck 6020, Austria.
  • Stühn LG; Houston Specialty Clinic, Houston, TX 77024, USA.
  • Haack TB; Houston Specialty Clinic, Houston, TX 77024, USA.
  • Posey JE; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam 3015 GD, The Netherlands.
  • Lupski JR; Pediatric Movement Disorders Program, Division of Pediatric Neurology, Barrow Neurological Institute, Phoenix Children's Hospital, Phoenix, AZ 85016, USA.
  • Lee H; Departments of Child Health, Neurology, and Cellular & Molecular Medicine, and Program in Genetics, University of Arizona College of Medicine-Phoenix, Phoenix, AZ 85004, USA.
  • Sarn NB; Pediatric Movement Disorders Program, Division of Pediatric Neurology, Barrow Neurological Institute, Phoenix Children's Hospital, Phoenix, AZ 85016, USA.
Hum Mol Genet ; 32(20): 2981-2995, 2023 Oct 04.
Article em En | MEDLINE | ID: mdl-37531237
ABSTRACT
Protein phosphatase 1 regulatory subunit 3F (PPP1R3F) is a member of the glycogen targeting subunits (GTSs), which belong to the large group of regulatory subunits of protein phosphatase 1 (PP1), a major eukaryotic serine/threonine protein phosphatase that regulates diverse cellular processes. Here, we describe the identification of hemizygous variants in PPP1R3F associated with a novel X-linked recessive neurodevelopmental disorder in 13 unrelated individuals. This disorder is characterized by developmental delay, mild intellectual disability, neurobehavioral issues such as autism spectrum disorder, seizures and other neurological findings including tone, gait and cerebellar abnormalities. PPP1R3F variants segregated with disease in affected hemizygous males that inherited the variants from their heterozygous carrier mothers. We show that PPP1R3F is predominantly expressed in brain astrocytes and localizes to the endoplasmic reticulum in cells. Glycogen content in PPP1R3F knockout astrocytoma cells appears to be more sensitive to fluxes in extracellular glucose levels than in wild-type cells, suggesting that PPP1R3F functions in maintaining steady brain glycogen levels under changing glucose conditions. We performed functional studies on nine of the identified variants and observed defects in PP1 binding, protein stability, subcellular localization and regulation of glycogen metabolism in most of them. Collectively, the genetic and molecular data indicate that deleterious variants in PPP1R3F are associated with a new X-linked disorder of glycogen metabolism, highlighting the critical role of GTSs in neurological development. This research expands our understanding of neurodevelopmental disorders and the role of PP1 in brain development and proper function.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno Autístico / Transtornos do Neurodesenvolvimento / Transtorno do Espectro Autista / Deficiência Intelectual Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno Autístico / Transtornos do Neurodesenvolvimento / Transtorno do Espectro Autista / Deficiência Intelectual Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article